Please enable JavaScript.

Coggle requires JavaScript to display documents.

Vasoactive Peptides (Pharmacology) - Coggle Diagram

- - - - ACE inhibitor reduces
        angiotensin Il and aldosterone secretion
        increases bradykinin
    - - aldosterone secretion
        increases bradykinin
    - - Oral
        Half-life:~2h but large doses used for duration of
        effect 12h
    - - Cough, teratogenic,
        hyperkalemia
  - - - Hypertension
    - - Oral
        Duration:6-8 h
    - - AT1, recéptor inhibitor;
        reduces effects of angiotensin II
    - - Teratogenic, hyperkalemia
  - - - Hypertension
    - - Oral
        Duration:12h
    - - reduces
        angiotensin I and I and aldosterone secretion
    - - Angioedema, renal
        impairment
- - - - Hereditary angioedema
    - - Subcutaneous
        Duration 2 h
    - - Kallikrein inhibitor
        reduces bradykinin levels
    - - Hypersensitivity reactions
  - - - Hereditary angioedema
    - - Subcutaneous
        Duration 1 h
    - - B2 bradykinin receptor
        blocker
    - - Hepatic toxicity, hypersensitivity reactions
- - - - Acute heart failure
    - - Parenteral
        Half-life: 18 min
    - - BNP receptor agonist
    - - Renal damage, hypotension
- - - - Antiemetic for chemotherapy-induced vomiting
    - - Oral
        Half-life: 9–13 h
    - - Tachykinin NK1 receptor antagonist
    - - Asthenia, hiccups
  - - - Topical for painful conditions (joints, post-herpetic neuralgia)
    - - Topical
        Duration: 4–6 h
    - - Releases substance P from nerve endings
    - - Burning, stinging, erythema
- - - - Pulmonary hypertension
    - - Oral
        Half-life: 5 h
    - - ETA and ETB receptor antagonists
    - - Hepatic impairment; possible teratogen